Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline ...

From shocking outliers to budget-friendly powerhouses, we've learned which cordless vacuums truly excel in battery life, ...

Scientists have shown that two previously separate modes of plant branching regulation can be connected, revealing the most ...

One powerful way to do this is through a routine called slow reveal graphs.

Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around ...

Jupiter Endovascular announced today that its Vertex catheter received FDA 510(k) clearance for the insertion of endovascular ...

At this grand event focusing on the deep integration of technology and innovation, Xu Yihan, Senior Executive Vice President ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $387.15, moving -1.08% from the previous trading session. This change lagged the S&P 500's daily loss of 0.1%. Meanwhile, the Dow ...

Vertex Pharmaceuticals Incorporated just reported a robust Q2 with earnings per share of $4.52, surpassing estimates and ...

Vertex Pharmaceuticals Incorporated has caught the keen eye of New England Research & Management Inc., investing a cool ...

There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA ...